ClinicalTrials.gg
CompletedNCT06336018Updated Jun 18, 2026

A Research Study on Etavopivat in Participants With and Without Liver Disease

A Phase 1 interventional study of Etavopivat in Liver Diseases, sponsored by Novo Nordisk A/S. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.

Enrollment
132nd of 269
48 · median 48
Started
2024
with 19 others
Phase 1
62 of 368
4 open now
Registered
336th of 368
by date

Among the 368 studies in Liver Diseases with a site in United States, this one is the 132nd largest by enrollment of the 269 interventional ones that give a count, is one of 20 that started in 2024, is one of 62 in phase 1, and was the 336th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 152 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 368 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days.

03

Conditions studied

  • Liver Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age 18 years or above at the time of signing the .
  • (BMI) between 18.5 and 42.0 kilogram per meter\^2 (kg/m\^2) (both inclusive) at screening.
  • Body weight greater than or equal to (>=) 40.0 kilogram (kg) at screening.

Specific inclusion criteria only for participants with hepatic impairment:

  • Participants with chronic (above 6 months), stable (no significant deterioration in hepatic function in last 2 months as determined by the investigator) hepatic impairment classified as class A, B or C, as assessed by the investigator and which is confirmed and documented by medical history, physical examination and at least one of the following: hepatic ultrasound, computerised axial tomography (CT) scan, magnetic resonance imaging (MRI), and/or liver .
  • Participants must be on a stable dose of medication and/or treatment regimen (e.g., no expectations of new medications nor changes to current medications within 14 days of dosing).

Specific inclusion criterion only for participants with normal hepatic function:

- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, (ECG), and laboratory safety tests performed during screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention or related products.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate methods.
  • Participation (i.e., signed ) in any interventional clinical study within 30 days or 5 times the half-life of the previous medical product (IMP) (if known), whichever is longer, before screening.
  • Any disorder, unwillingness or inability, except for conditions associated with hepatic impairment in the group of participants with compromised hepatic function, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Participant is unable to refrain from or anticipates the use of, for 7 days prior to dosing and throughout the study, any drug known to be:

    • an inhibitor of uridine 5'-diphospho-glucuronosyltransferase (UGT) 2B7,
    • a strong inhibitor of cytochrome P450 (CYP)3A4 or CYP2C9,
    • a potent inhibitor of permeability glycoprotein (P-gp).
  • Participant is unable to refrain from or anticipates the use of, for 28 days prior to dosing and throughout the study, any drug known to be:

    • an inducer of UGT2B7,
    • a strong or moderate inducer of , including St. John's Wort,
    • a strong inducer of CYP2C9,
    • a potent inducer of P-gp.
  • Participant is unable to refrain from or anticipates the use of any medications or substances prohibited in the study.

Specific exclusion criterion only for participants with hepatic impairment:

- Clinical signs of an acute hepatitis (viral as well as non-viral) or positive tests of virus surface antigen (HBsAg) (unless hepatitis B virus titre is negative) or antibody tests of virus (HCV-Ab) (unless negative polymerase chain reaction [PCR] for hepatitis C virus).

Specific exclusion criteria only for participants with normal hepatic function:

  • Diagnostic test results positive for hepatitis B or hepatitis C infection.
  • History of diabetes mellitus or (HbA1c) greater than or equal to 5 percent (48 millimoles per mole [mmol/mol]) at screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Mild hepatic impairment: Etavopivat dose 2

    Participants will receive a single dose of oral etavopivat.

    Drug: Etavopivat

  • Experimental
    Moderate hepatic impairment: Etavopivat dose 2

    Participants will receive a single dose of oral etavopivat.

    Drug: Etavopivat

  • Experimental
    Healthy matched controls: Etavopivat dose 2

    Participants will receive a single dose of oral etavopivat.

    Drug: Etavopivat

  • Experimental
    Severe hepatic impairment: Etavopivat dose 1

    Participants will receive a single dose of oral etavopivat.

    Drug: Etavopivat

  • Experimental
    Healthy matched controls: Etavopivat dose 1

    Participants will receive a single dose of oral etavopivat.

    Drug: Etavopivat

Interventions

  • Participants will receive a single dose of etavopivat orally.

06

What researchers measure

Primary outcomes

  1. Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose (AUC0-inf, etavopivat)

    Measured in hours\*nanogram per milliter (h\*ng/mL).

    Time frame: From IMP administration on day 1 to completion of the end of study visit (day 9)

  2. Maximum observed etavopivat plasma concentration after a single dose (Cmax, etavopivat)

    Measured in nanogram per milliter (ng/mL).

    Time frame: From IMP administration on day 1 to completion of the end of study visit (day 9)

Secondary outcomes

  1. Area under the etavopivat plasma concentration-time curve from 0 hours to the last quantifiable concentration after a single dose (AUC0-last, etavopivat)

    Measured in h\*ng/mL.

    Time frame: From IMP administration on day 1 to completion of the end of study visit (day 9)

  2. Time to maximum observed etavopivat plasma concentration after a single dose (tmax, etavopivat)

    Measured in hours.

    Time frame: From IMP administration on day 1 to completion of the end of study visit (day 9)

  3. Terminal half-life for etavopivat after a single dose (t1/2, etavopivat)

    Measured in hours.

    Time frame: From IMP administration on day 1 to completion of the end of study visit (day 9)

  4. Apparent plasma clearance of etavopivat after a single dose (CL/Fetavopivat)

    Measured in liter per hour (L/h).

    Time frame: From IMP administration on day 1 to completion of the end of study visit (day 9)

  5. Apparent volume of distribution of etavopivat after a single dose based on plasma concentration values (Vz/Fetavopivat)

    Measured in liter (L).

    Time frame: From IMP administration on day 1 to completion of the end of study visit (day 9)

  6. Number of adverse events (AEs)

    Measured as count of events.

    Time frame: From IMP administration on day 1 to completion of the end of study visit (day 9)

07

Study locations

5 sites
  • Cure Clinical Research LLC
    Orange, California 92866, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32806, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Amer. Rrsch Corp-TX Liver Inst
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Aug 2025, 14 months.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 14 months is close to that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 28, 2024
StartActual
May 20, 2024
Primary completionActual
Aug 1, 2025
CompletionActual
Aug 1, 2025
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06336018
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
May 20, 2024
Primary completion
Aug 1, 2025
Completion
Aug 1, 2025
Last update
Jun 18, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etavopivat

Start the discussion